IBRNvsXBIETF Comparison
VS
iShares Neuroscience and Healthcare ETF (IBRN) belongs to the Healthcare Technology segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. IBRN's top 2 sector exposures are Healthcare and Non-Corporate. In contrast, XBI's top sector exposures are Healthcare and Finance. IBRN is more expensive with a Total Expense Ratio (TER) of 0.47%, versus 0.35% for XBI. IBRN is up 21.97% year-to-date (YTD) with +$2M in YTD flows. XBI performs better with 35.68% YTD performance, and +$892M in YTD flows. Run a side-by-side ETF comparison of IBRN and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IBRN vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/02/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IBRN XBI | +7.59%+12.22% | +16.53%+29.54% | +21.97%+35.68% | +57.77%+78.69% | +75.49%+109.09% | n/a+21.75% |
| Flows | IBRN XBI | +$2M+$670M | +$2M+$1.29B | +$2M+$892M | +$2M+$1.83B | +$759K+$97M | -+$1.60B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IBRN XBI | +24.72%+30.78% | +25.80%+27.89% | +25.18%+28.27% | n/a+32.91% |
| Max drawdown | IBRN XBI | -9.28%-10.46% | -9.28%-10.46% | -34.98%-32.94% | n/a-54.07% |
| Max drawdown duration | IBRN XBI | 40d40d | 40d40d | 338d331d | n/a1685d |
Trading data
IBRN | XBI | |
Last sale 9/3/2026 at 3:09 PM | $39.41 | $164.27 |
| Previous close 09/02/2026 | $39.46 | $165.37 |
| Consolidated volume 09/02/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IBRN | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/3/2026 at 3:09 PM
Live
Closed
IBRN | XBI | |
|---|---|---|
| Last price | $39.41 | $164.27 |
| 1D performance | -0.12% | -0.67% |
| AuM | $7.88 M | $11.50 B |
| E/R | 0.47% | 0.35% |
Characteristics
IBRN | XBI | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | iShares | State Street Investment Management |
| Benchmark | NYSE FactSet Global Neuro Biopharma and MedTech Index | S&P Biotechnology Select Industry Index |
| N° of holdings | 69 | 147 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 24, 2022 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
IBRN
USA
73.57%
Other
26.43%
XBI
USA
95.07%
Other
4.93%
Sectors
IBRN
Healthcare
99.87%
Other
0.13%
XBI
Healthcare
99.19%
Other
0.81%
Advertisement
Diversification
IBRN
Total weight of top 15 holdings out of 15
64.26%
XBI
Total weight of top 15 holdings out of 15
20.29%
Top 15 holdings
Data as of July 31, 2026
IBRN
Dianthus Therapeutics, Inc.
5.45%
Xenon Pharmaceuticals, Inc.
4.83%
Praxis Precision Medicines, Inc.
4.72%
ACADIA Pharmaceuticals, Inc.
4.66%
Arrowhead Pharmaceuticals, Inc.
4.65%
Alkermes Plc
4.55%
Neurocrine Biosciences, Inc.
4.41%
Scholar Rock Holding Corp.
4.31%
PTC Therapeutics, Inc.
4.15%
Biogen, Inc.
4.15%
Axsome Therapeutics, Inc.
3.93%
argenx SE
3.82%
Denali Therapeutics, Inc.
3.76%
Dyne Therapeutics, Inc.
3.53%
Edgewise Therapeutics, Inc.
3.35%
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
Frequently asked questions about IBRN and XBI
How have the IBRN and XBI ETFs performed in 2026?
As of September 2, 2026, IBRN is up 21.97% year-to-date (YTD), while XBI has returned 35.68%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: IBRN or XBI?
Year-to-date, the IBRN ETF saw +$2M in flows, compared to +$892M for XBI.
Which ETF is more volatile: IBRN or XBI?
Over the past year, IBRN had a volatility of 25.8%, while XBI experienced 27.89%.
Which ETF is bigger: IBRN or XBI?
As of September 2, 2026, IBRN holds $7.88 M in assets under management (AUM), while XBI manages $11.50 B.
What sectors do the IBRN and XBI ETFs invest in?
IBRN leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the IBRN ETF and XBI ETF?
IBRN top holdings include Dianthus Therapeutics, Inc., Xenon Pharmaceuticals, Inc. and Praxis Precision Medicines, Inc.. XBI holds in its top three: Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc..
Which ETF is more diversified: IBRN or XBI?
IBRN holds 69 securities with 64.26% of its assets in the top 15. XBI has 151 securities and a top 15 weight of 20.29%.
Advertisement
Latest news about IBRN & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
